Compass Therapeutics (CMPX) Other financing activities (2022 - 2026)

Compass Therapeutics (CMPX) posted Other financing activities of $3.9 million for Q1 2026, up 18252.38% sequentially from $21000.0 in Q3 2023.

Compass Therapeutics (CMPX) Other financing activities (2022 - 2026) Analysis & Trends

Compass Therapeutics has reported Other financing activities for 3 years, with the latest figure at $3.9 million in Q1 2026.

Quarterly Other financing activities changed N/A year-over-year to $3.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (changed N/A YoY) and the FY2025 annual result came in at $1.3 million, changed N/A from the prior year.
Other financing activities grew to $3.9 million in Q1 2026 per CMPX's latest filing, from $21000.0 in the prior quarter.
Over five years, Other financing activities peaked at $3.9 million in Q1 2026 and troughed at $5000.0 in Q3 2022.
A 3-year average of $786200.0 and a median of $21000.0 in 2023 frame the typical range for Other financing activities.
The widest YoY moves for Other financing activities: up 320.0% in 2023, down 320.0% in 2023.
Over 3 years, Other financing activities stood at $10000.0 in 2022, then soared by 110.0% to $21000.0 in 2023, then soared by 18252.38% to $3.9 million in 2026.
According to Business Quant data, Other financing activities over the past three periods registered $3.9 million, $21000.0, and $41000.0 for Q1 2026, Q3 2023, and Q1 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Compass Therapeutics	405.20 Mn	405.20 Mn	-

Download Data